BCL2L12 Protein, Human, Recombinant (GST Tag)


BCL2L12 Protein, Human, Recombinant (GST Tag): Product Information

> 95 % as determined by SDS-PAGE
Please contact us for more information.
Testing in progress
Protein Construction
A DNA sequence encoding the human BCL2L12 (Q9HB09-1) (Pro147-Lys227) was fused with the GST tag at the N-terminus.
Expressed Host
E. coli
Predicted N Terminal
Molecule Mass
The recombinant human BCL2L12/GST chimera consists of 314 amino acids and has a predicted molecular mass of 36 kDa. It migrates as an approximately 33 kDa band in SDS-PAGE under reducing conditions.
Lyophilized from sterile PBS, pH 8.0.
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -70℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

BCL2L12 Protein, Human, Recombinant (GST Tag): Images

BCL2L12 Background Information

BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML. BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide. BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy.
Full Name
BCL2-like 12 (proline rich)
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait